Summary of Key Points
The National Medical Products Administration has recently required all oral formulations of Ganmaoling (in the form of granules, capsules, tablets, or tea) to have their instructions revised uniformly. The main additions include warnings such as "do not drive or work at heights while taking the medication," as well as improved information on ingredients, side effects, and contraindications. This revision affects companies, pharmacies, and consumers. Companies must complete the registration process by October 2026. Pharmacies believe that the impact on sales is manageable and that it can reduce customer complaints. Consumers, especially those in specific professions like driving, need to be aware of alternative medications that do not cause drowsiness.
What Key Changes Have Been Made to the Instructions? And Why?
The revision mainly includes four major sections: warnings, contraindications, side effects, and precautions. The most important changes are three mandatory warnings:
1. Clear Identification of Ingredients: The instructions now explicitly state that the product contains acetaminophen (for fever reduction and pain relief), chlorpheniramine maleate (for anti-allergy effects), and caffeine (to boost alertness, although it may still cause drowsiness).
2. Prohibitions on Driving, Drinking Alcohol, and Concurrent Use: It is forbidden to drive or work at heights while taking the medication due to the potential for drowsiness caused by chlorpheniramine maleate. Drinking alcohol is also prohibited as it can harm the liver when taken with acetaminophen. Additionally, concurrent use with other cold medications containing similar ingredients (such as Tylenol or Gan Kang) should be avoided to prevent kidney damage.
3. Risk of Kidney Damage: The instructions warn that combining this medication with other antipyretic and analgesic drugs may increase the risk of kidney damage.
The list of side effects has been expanded to include skin allergies, dizziness, stomach pain, and liver or kidney discomfort, providing a more comprehensive overview of potential risks.
What Do Manufacturers Need to Do? Is There a Deadline?
All manufacturers of Ganmaoling (such as China Resources Sanjiu) must follow the schedule:
- First Phase: Submit the revised instructions to the provincial medical products administration for registration by October 15, 2026. Medications produced after this date must use the new instructions.
- Second Phase: Within 9 months after registration, replace the instructions on all existing medications or inform patients about the changes via text messages, apps, etc.
Manufacturers also need to research the causes of these side effects and train doctors and pharmacists on proper medication use.
Although leading companies (such as China Resources Sanjiu, whose Ganmaoling product generates annual sales of over 2 billion yuan) have not been interviewed yet, they cannot avoid this requirement. Failure to comply may result in penalties.
Why Do Pharmacies See This as a Good Thing? Can It Reduce Disputes?
Chain pharmacy managers consider the revision beneficial for two reasons:
1. Reduced Complaints: Previously, customers who experienced drowsiness after taking Ganmaoling (such as causing accidents while driving) would sue the pharmacy. With the new instructions clearly stating "do not drive," responsibilities are clearer, and pharmacies can follow them to avoid disputes.
2. Availability of Alternatives: Since Ganmaoling is a seasonal medication, there are other options on the market that do not contain chlorpheniramine maleate (e.g., some traditional Chinese medicines or second-generation antihistamines). This allows customers in professions requiring clarity of mind (like drivers or workers at heights) to switch to alternative products without affecting overall sales.
Pharmacies also need to ensure that they sell only medications with the revised instructions. They should ask elderly patients and drivers if they plan to drive or work at heights and recommend suitable alternatives. For example, in a case in Sichuan where a patient died from chlorpheniramine poisoning due to missing instructions, the pharmacy was liable for compensation (87,000 yuan).
What Should Consumers Be Aware Of When Taking This Medication?
- General Consumers: Always read the new instructions before taking the medication. Avoid drinking alcohol and do not take it with other cold medications.
- If drowsiness occurs after taking the medication, do not drive or engage in activities that require alertness.
For Drivers/Workers at Heights:
- Choose cold medications that do not contain chlorpheniramine maleate (e.g., Lianhua Qingwen granules or Pudilan anti-inflammatory tablets). Alternatively, ask the pharmacy for options that do not cause drowsiness.
- If you are unsure about the ingredients, inform the pharmacy of your occupation so they can recommend appropriate medications.
It's Important to Note: Ganmaoling is not a banned drug; it just requires extra attention to its side effects. Short-term use is generally safe, but specific groups need to choose the right medication.
Why Is This Revision Being Made Now? Ganmaoling Is So Popular!
Ganmaoling is a combination of traditional Chinese and Western medicine with very high sales. In 2023, its sales surpassed those of Lianhua Qingwen, making it the most popular cold medication in urban pharmacies. Its large market presence means that many people are affected by its potential risks. Previous warnings from traffic authorities about driving under the influence, along with cases of adverse reactions, have led to this mandatory revision. The goal is to ensure public safety, as a "national drug" should provide clear information about its potential dangers.
In summary, this revision is not intended to ban Ganmaoling but to make it safer. It represents a compliance requirement for companies, reduces issues for pharmacies, and provides additional guidance for consumers, especially those in at-risk groups. After all, taking medication is meant to help with illness, not to pose new risks.